"By negotiating with just the PBM side, you're kind of limiting the total benefit [of reduced costs]. And that could be a very interesting discussion in the future — maybe do a reverse auction at the member level, which would be very hard but very aspirational."
— Ashraf Shehata, KPMG's national sector leader for health care
and life sciences, spoke with AIS's RADAR
on Drug Benefits about the upsides and downsides of New Jersey's
reverse-auction PBM procurement model.
No comments:
Post a Comment